Outlook Therapeutics rises after US FDA accepts eye disease treatment for review

Outlook Therapeutics

16/06/2026 14:49

Updates
** Shares of Outlook Therapeutics OTLK.O rise 11.6% to $1.29
** Drugmaker says the U.S. FDA has accepted for review its resubmitted marketing application for ONS-5010, branded as Lytenava, after declining approval in December
** OTLK's Lytenava targets wet age-related macular degeneration, a common eye disease that causes vision loss due to leaking blood vessels in the retina
** Resubmission has been classified as a Class 1 review, with a target action date of July 29, co says
** Lytenava is a specific, officially authorized formulation of FDA-approved drug bevacizumab
** Including session's moves, stock down 24% this year

 (Reporting by Siddhi Mahatole)
 ((siddhi.mahatole@thomsonreuters.com))